AnyFlu Powder 75 mg (Oseltamivir Phosphate)

Adult dose

Treatment of influenza A and influenza B virus infections: Start treatment on the first or second day after influenza symptoms appear. This medicine may be taken with or without food; taking it with food may improve tolerability in some patients. Adults and adolescents 13 years of age and older: Administer 75 mg of oseltamivir orally twice daily for 5 days. Adults and adolescents 13 years of age and older who have difficulty swallowing capsules should use this medicine for dosing. Patients with renal impairment (treatment): No dosage adjustment is required for patients with a creatinine clearance of 60 mL/min or greater. For patients with a creatinine clearance of 30 ~ 60 mL/min, a reduced dose of 30 mg twice daily for 5 days is recommended. For patients with a creatinine clearance of 10 ~ 30 mL/min, a reduced dose of 30 mg once daily for 5 days is recommended. Patients receiving intermittent hemodialysis should receive a 30mg dose of this medicine after each dialysis session to maintain blood concentrations within the therapeutic range, and treatment should not exceed 5 days. If influenza symptoms develop during the 48 hours between dialysis sessions, the dose may be given before dialysis begins. For peritoneal dialysis, a single 30mg dose of this medicine after dialysis is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. Patients with hepatic impairment (treatment): No dosage adjustment is required for treatment of adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9). Prevention of influenza A and influenza B virus infections—Adults and adolescents 13 years of age and older: For close contacts of an infected person, administer 75 mg of oseltamivir orally once daily for 10 days. Start administration within 2 days of contact with the infected person. The recommended dose for prevention during an influenza outbreak is 75 mg once daily. The safety and efficacy of this medicine have been demonstrated for up to 6 weeks. The preventive effect continues while the medicine is being taken. Patients with renal impairment (prevention): No dosage adjustment is required for patients with a creatinine clearance of 60 mL/min or greater. For patients with a creatinine clearance of 30 ～ 60 mL/min, a reduced dose of 30 mg once daily is recommended. For patients with a creatinine clearance of 10 ～ 30 mL/min, a reduced dose of 30 mg once daily every other day is recommended. Patients receiving intermittent hemodialysis should receive a 30mg dose of this medicine after every 2 dialysis sessions to maintain blood concentrations within the therapeutic range. The first dose may also be given before dialysis begins. For peritoneal dialysis, administration of 30mg of this medicine after dialysis once weekly is recommended. The pharmacokinetics of oseltamivir have not been studied in patients with end-stage renal disease who are not receiving dialysis (e.g., creatinine clearance less than 10mL/min); therefore, no recommended dose is available for these patients. Patients with hepatic impairment (prevention): No dosage adjustment is required for prevention in adult patients with mild to moderate hepatic impairment (Child-Pugh score ≤ 9).

Child dose

Treatment of influenza A and influenza B virus infections—Children 1 to 12 years of age: Pediatric patients weighing more than 40 kg who can swallow capsules may take a 75mg capsule twice daily or a 30mg capsule and a 45mg capsule twice daily instead of the recommended dose of this medicine. Weight ≤ 15 kg: 30 mg (packet) twice daily, for 5 days. Weight 15 kg<, ≤ 23 kg: 45 mg (packet) twice daily, for 5 days. Weight 23 kg<, ≤ 40 kg: 60 mg (two 30mg packets) twice daily, for 5 days. Weight > 40 kg: 75 mg (packet) twice daily, for 5 days. Infants 2 weeks to less than 1 year of age: The recommended dose for pediatric patients 2 weeks to 12 months of age is 3mg/kg of this medicine orally twice daily for 5 days. This does not apply to infants with a postconceptional age of less than 36 weeks. Pediatric patients who have difficulty taking this medicine as a powder should use the suspension. Weight 3 kg: 9 mg twice daily; suspension (6mg/mL) 1.5mL twice daily. Weight 4 kg: 12 mg twice daily; suspension (6mg/mL) 2.0mL twice daily. Weight 5 kg: 15 mg twice daily; suspension (6mg/mL) 2.5mL twice daily. Weight 6 kg: 18 mg twice daily; suspension (6mg/mL) 3.0mL twice daily. Weight 7 kg: 21 mg twice daily; suspension (6mg/mL) 3.5mL twice daily. Weight 8 kg: 24 mg twice daily; suspension (6mg/mL) 4.0mL twice daily. Weight 9 kg: 27 mg twice daily; suspension (6mg/mL) 4.5mL twice daily. Weight 10 kg: 30 mg twice daily; suspension (6mg/mL) 5.0mL twice daily. This table does not include all possible weights for this patient group. A dose of 3mg/kg of this medicine is recommended for children younger than 1 year. Prevention of influenza A and influenza B virus infections—Children 1 to 12 years of age: Pediatric patients weighing more than 40 kg who can swallow capsules may take a 75mg capsule once daily or a 30mg capsule and a 45mg capsule once daily for 10 days instead of the recommended dose of this medicine. Weight ≤ 15 kg: 30 mg (packet) once daily, for 10 days. Weight 15 kg<, ≤ 23 kg: 45 mg (packet) once daily, for 10 days. Weight 23 kg<, ≤ 40 kg: 60 mg (two 30mg packets) once daily, for 10 days. Weight > 40 kg: 75 mg (packet) once daily, for 10 days. The safety and efficacy of prevention of influenza A and B virus infections in children younger than 1 year have not been evaluated.

This medication is used for the treatment and prevention of patients infected with the influenza virus, and cannot replace influenza vaccines. Therefore, it is important to receive annual influenza vaccination even while taking this medication. This medication has been proven effective only against influenza A and B viruses, and its safety and efficacy have not been confirmed for other infections. Rarely, neuropsychiatric adverse events, such as seizures, delirium, or unusual behavior, have been reported in children and adolescents taking this medication, especially those patients should be closely monitored for unusual behaviors after taking it. Children and adolescents over 10 years old using this medication may have a risk of accidents due to unusual behavior, and it is generally not used unless the patient is high-risk. During treatment with this medication, caregivers should ensure that children or adolescents are not left alone, especially for at least 2 days. Patients with hypersensitivity to this medication should not use it, and dose adjustments may be necessary for those with impaired kidney function or may not be recommended. Patients at high risk, for example, those with asthma, chronic bronchitis, or immunosuppressive conditions, should use this medication with caution. Common side effects of this medication include nausea, vomiting, headache, and pain, which are mostly transient and mild symptoms. Rarely, anaphylaxis, skin rash, liver function abnormalities, acute renal failure, neuropsychiatric adverse symptoms may occur, and if any unusual symptoms appear, healthcare professionals should be informed immediately. Pregnant or breastfeeding women should carefully consider the risks and benefits of using this medication. Particular caution is needed in children, especially infants under 1 year old, as the safety and efficacy of this medication have not been sufficiently established in this group. Elderly patients generally do not need dose adjustments, but should be closely monitored considering reduced physical functions. This medication has a low potential for interactions with specific drugs, but caution is required when used in conjunction with drugs affecting renal excretion. Adhere to the prescribed dosage and administration; if a dose is missed, take it as soon as possible unless it is too close to the next dose, in which case skip it. This medication should be stored out of the reach of children and should not be transferred to another container.

• nausea
• vomiting
• headache
• pain
• unstable angina
• anemia
• pseudomembranous colitis
• pneumonia
• peritonsillar abscess
• humeral fracture

This medication must be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain the storage temperature between 1°C and 30°C to preserve the drug's effectiveness.

Appearance

White or yellowish-brown powder

Package unit

10 packets per box